Italia markets open in 4 hours 41 minutes

Seagen Inc. (0A8R.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
178,88-0,41 (-0,23%)
Alla chiusura: 03:08PM BST

Seagen Inc.

21823 30th Drive SE
Bothell, WA 98021
United States
425 527 4000
https://www.seagen.com

Settore/i
Settore
Impiegati a tempo pieno2.675

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Roger D. Dansey M.D.Chief Medical Officer & Interim CEO1,53MN/D1956
Dr. Clay B. Siegall Ph.D.Co-Founder, Chairman, Pres & CEO (Leave of Absence)3,09M42,87M1961
Mr. Todd E. SimpsonChief Financial Officer1,17M13,84M1961
Ms. Jean I. Liu J.D., M.S.Chief Legal Officer1,11M8,23M1968
Mr. Charles R. RompExec. VP of Commercial U.S.1,02MN/D1968
Dr. Vaughn B. Himes Ph.D.Chief Technical OfficerN/DN/D1961
Peggy PinkstonSr. VP of Investor RelationsN/DN/DN/D
Mr. David CaouetteVP of Corp. CommunicationsN/DN/DN/D
Ms. Natasha A. HerndayExec. VP of Corp. Devel. & Alliance ManagementN/DN/D1972
Mr. Matt SkeltonVP of MarketingN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Governance aziendale

L'ISS Governance QualityScore di Seagen Inc. al 1 luglio 2022 è 4. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 2; diritti degli azionisti: 5; retribuzione: 4.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.